



MARKET RELEASE

21 November 2017

Zelda Therapeutics Limited

TRADING HALT

The securities of Zelda Therapeutics Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the response by the Company to an ASX query. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday, 23 November 2017 or when the response is released to the market.

Security Code: ZLD

Isabelle Andrews

Adviser, Listings Compliance (Perth)



21 November 2017

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

Attention: Isabelle Andrews
By email only: isabelle.andrews@asx.com.au

Dear Sir

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Zelda Therapeutics Limited (ASX: ZLD) requests the granting of a trading halt in ZLD's ordinary securities listed on the ASX pending the response to an ASX price query.

It is requested that the trading halt apply immediately until the earlier of ZLD making the announcement concerning a response to the ASX price query, or the opening of trading on Thursday, 23 November 2017.

ZLD confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely

Tim Slate
Company Secretary

Corporate

Mr Harry Karelis
Executive Chairman
Mobile: +61 413 056 328
hkarelis@zeldatherapeutics.com

Investors

Dr Stewart Washer
Executive Director
Mobile: +61 418 288 212
swasher@zeldatherapeutics.com



About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics ("Zelda") is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A human clinical trial programme focused on insomnia, autism and eczema with activities in Australia and Chile.
- A pre-clinical research programme examining the effect of cannabinoids in breast, brain and pancreatic cancer. It has partnered with the world's leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer.